Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases

A compound having the formula:

• or a pharmaceutically acceptable salt thereof,
• wherein:
• Q is:
• A is phenyl, 5 or 6-membered heteroaryl, 5 to 7-membered monocyclic cycloalkyl or 5 to 7-membered heterocycloalkyl, each of which can be optionally substituted with up to four R5 groups;
• V is N or —C(R4)—;
• W is N or —CH—;
• X is —(CHR8)n—O—, —C(O)—O—,
• Y1 is N or —C(R5)—;
• Y2 is N or —C(R5)—;
• Z is N, —C(R5)— or —C(O)—, such that when Z is —C(O)—, then the endocyclic double bond depicted in formula (Q2) between Z and Y1 is understood to be a single bond;
• R1 represents up to 4 optional ring substituents, which can be the same or different, and are independently selected from halo, C1-C6 alkyl, C1-C6 haloalkyl, phenyl, 3 to 7-membered monocyclic cycloalkyl, —O—(C1-C6 alkyl), —O—(C1-C6 haloalkyl) and —CN;
• R2 is —C(O)N(R6)(R7) or —C(O)O—(C1-C6 alkyl);
• R3 is H, 4- to 6-membered heterocycloalkyl, 5 or 6-membered heteroaryl, —N(R11)2, halo, —CN, —N(R11)2, —C(O)O—(C1-C6 alkyl) or —N(R9)—S(O)n—R10, wherein said 5 or 6-membered heterocycloalkyl can optionally have one of its ring carbon atoms replaced with a carbonyl group;
• R4 is selected from H, halo, C1-C6 alkyl, 3 to 7-membered monocyclic cycloalkyl, C1-C6 haloalkyl, —O—(C1-C6 alkyl), —C(OH)—C(O)OR11 and —O—(C1-C6 haloalkyl);
• each occurrence of R5 is independently selected from H, halo, C1-C6 alkyl, C1-C6 haloalkyl, —O—(C1-C6 alkyl), —O—(C1-C6 haloalkyl) and —CN, wherein said C1-C6 alkyl group can be optionally substituted with —OH or —N(R11)2;
• R6 and R7 are each independently selected from hydrogen, —C(O)R11, —C(O)OR11, —C(O)C(O)OR11, C1-C6 alkyl, C1-C6 hydroxyalkyl, phenyl, 3 to 7-membered monocyclic cycloalkyl, 3 to 7-membered monocyclic heterocycloalkyl and 5 or 6-membered monocyclic heteroaryl;
• each occurrence of R8 is independently selected from H, halo, —OH, C1-C6 alkyl, C1-C6 hydroxyalkyl, phenyl, 5 or 6-membered monocyclic heteroaryl, —N(R11)2, C1-C6 haloalkyl, —(C1-C3 alkylene)p-(3 to 7-membered monocyclic cycloalkyl), —(C1-C3 alkylene)p-O—(C1-C6 alkyl), —(C1-C3 alkylene)p-N(R11)2, —(C1-C3 alkylene)-NHC(O)—(C1-C6 alkyl), —(C1-C3 alkylene)-OC(O)(C1-C6 alkyl)NHC(O)O—(C1-C6 alkyl), —(C1-C3 alkylene)-OC(O)-(3 to 7-membered monocyclic heterocycloalkyl), —(C1-C3 alkylene)-NHC(O)(3 to 7-membered monocyclic heterocycloalkyl), —CH(O—(C1-C6 alkyl))2, —O—(C1-C6 haloalkyl), —C(O)OR11, —C(O)N(R11)2, —CH2OC(O)CH(NH2)—(C1-C6 alkyl), —NHS(O)2—(C1-C6 alkyl), —CH2NHCH(R11)C(O)OR11, —NR11—(C1-C3 alkylene)-N(R11)2, —NR11—(C1-C3 alkylene)-(3 to 7-membered monocyclic heterocycloalkyl), —NR11—(C1-C6 hydroxyalkyl) and —CN, or two R8 groups and the common carbon atom to which they are attached, can join to form a spirocyclic ring selected from 3 to 7-membered monocyclic cycloalkyl and 3 to 7-membered monocyclic heterocycloalkyl;
• R9 is selected from H, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, benzyl, —(C1-C3 alkylene)-(3 to 7-membered monocyclic cycloalkyl) and 3 to 7-membered monocyclic cycloalkyl, wherein said C1-C6 alkyl group can be optionally substituted with a group selected from —N(R11)2, —OR11, —COOH, —C(O)N(R11)2, —S(O)2N(R11)2 and 3 to 7-membered monocyclic heterocycloalkyl and wherein the phenyl moiety of said benzyl group can be optionally substituted with a boronic acid group;
• R10 is selected from H, C1-C6 alkyl, C1-C6 haloalkyl, phenyl, 3 to 7-membered monocyclic cycloalkyl, 3 to 7-membered monocyclic heterocycloalkyl and 5 or 6-membered monocyclic heteroaryl, wherein said C1-C6 alkyl group can be optionally substituted with a group selected from —N(R11)2, —OR11, —COOH, —C(O)N(R11)2, and —S(O)2N(R11)2;
• each occurrence of R11 is independently selected from H, C1-C6 alkyl, and 3 to 7-membered monocyclic cycloalkyl;
• each occurrence of n is 1, 2 or 3;
• and
• each occurrence of p is 0 or 1.